Posted 09 February 2015
A class-action suit has been filed against Quincy Bioscience LLC, which has marketed Prevagen for several years. The company claims that the product works by re-supplying memory-related proteins that decline as people age. The complaint charged:
- The product cannot work as advertised because its only purported active ingredient, apoaequorin (a protein), is completely destroyed by the digestive system and transformed into common amino acids no different than those derived from other common food products.
- The amount of amino acids Prevagen adds to the user’s intake are trivial in comparison to normal dietary intake.
- Claims that clinical tests demonstrate that Prevagen will improve memory and support healthy brain function, sharper mind, and clearer thinking are false.
- Studies touted in Prevagen’s marketing campaign “if they exist at all, are, on their face, so seriously flawed that they demonstrate nothing regarding Prevagen.”
In 2012, the FDA warned Quincy that (a) several claims made for Prevagen were illegal, (b) clinical trials it had sponsored were illegal because they lacked FDA approval, (c) the company had failed to adequately report adverse reactions to its products, and (d) the company had failed to comply with various Good Manufacturing Practices.